HbA 1c variability is associated with microalbuminuria development in type 2 diabetes: A 7-year prospective cohort study

Diabetologia

Volumn 55, Issue 12, 2012, Pages 3163-3172

  Hsu, C C ^a,b   Chang, H Y ^a   Huang, M C ^c   Hwang, S J ^d   Yang, Y C ^e   Lee, Y S ^a   Shin, S J ^f   Tai, T Y ^g  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g Taipei Jen Chi Relief Institute   (Taiwan)

Author keywords

HbA 1c variability; Microalbuminuria; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; URINALYSIS; ALBUMINURIA; ANALYSIS OF VARIANCE; DISEASE COURSE; GLUCOSE BLOOD LEVEL; INCIDENCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; TAIWAN; TIME; URINE;

ALBUMINURIA; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 84868195634     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2700-4     Document Type: Article

References (33)

1. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 329:977-986
2. The Diabetes Control and Complications Trial Research Group (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44:968-983
3. Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412
4. Zoppini G, Verlato G, Targher G et al (2009) Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? Nutr Metab Cardiovasc Dis 19:334-339
5. Snell-Bergeon JK, Roman R, Rodbard D et al (2010) Glycaemic variability is associated with coronary artery calcium in men with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. Diabet Med 27:1436-1442
6. Takao T, Ide T, Yanagisawa H et al (2011) The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients. Diabetes Res Clin Pract 91:e40-42
7. Su G, Mi S, Tao H et al (2011) Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 10:19
8. Zaccardi F, Pitocco D, Ghirlanda G (2009) Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab Res Rev 25:199-207
9. Ceriello A, Ihnat MA (2010) 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 27:862-867
10. Kilpatrick ES, Rigby AS, Atkin SL (2010) For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med 27:868-871
11. Siegelaar SE, Holleman F, Hoekstra JBL, DeVries JH (2010) Glucose variability; does it matter? Endocr Rev 31:171-182
12. Nalysnyk L, Hernandez-Medina M, Krishnarajah G (2010) Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 12:288-298
13. Waden J, Forsblom C, Thorn LM et al (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649-2655
14. Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB (2011) A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care 34:1011-1013
15. Kilpatrick ES, Rigby AS, Atkin SL (2008) A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 31:2198-2202
16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
17. Huang MC, Hsu CC, Wang HS, Shin SJ (2010) Prospective randomized controlled trial to evaluate effectiveness of registered dietitian-led diabetes management on glycemic and diet control in a primary care setting in Taiwan. Diabetes Care 33:233-239
18. Hsu CC, Chang HY, Huang MC et al (2011) Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study. Diabetes Care 34:982-987
19. Haller H, Ito S, Izzo JL Jr et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907-917
20. Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ (2007) Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50:2280-2288
21. Siegelaar SE, Kilpatrick ES, Rigby AS et al (2009) Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52:2229-2232
22. Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486-1490
23. Siegelaar SE, Kerr L, Jacober SJ, Devries JH (2011) A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 34:855-857
24. Muggeo M, Verlato G, Bonora E et al (1997) Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 96:1750-1754
25. Muggeo M, Zoppini G, Bonora E et al (2000) Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 23:45-50
26. Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM (2003) Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complications 17:78-81
27. Monnier L, Colette C, Owens DR (2008) Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2:1094-1100
28. Nathan DM, Turgeon H, Regan S (2007) Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 50:2239-2244
29. Nathan DM, Cleary PA, Backlund J-YC et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653
30. Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-1687
31. Ceriello A, Esposito K, Piconi L et al (2008) Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57:1349-1354
32. El-Osta A, Brasacchio D, Yao D et al (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205:2409-2417
33. National Kidney Foundation KDOQI Clinical Practice Guidelines. Available from http://www.kidney.org/professionals/kdoqi/guidelines-ckd/p5-lab-g5.htm. Accessed 5 May 2012